NCT04085250进行中（未招募）2 期
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University3 个研究点 分布在 1 个国家目标入组 264 人开始时间: 2019年11月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 264
- 试验地点
- 3
- 主要终点
- Progression-free Survival
研究概览
简要总结
The phase II, randomised Study is to explore the efficacy and safety of nivolumab as consolidation therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following neoadjuvant chemotherapy plus nivolumab and definitive concurrent chemoradiation therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For inclusion in neoadjuvant therapy, patients should fulfil the following criteria:
- •Provision of signed, written and dated informed consent prior to any study specific procedures；
- •Male or female aged 18~75 years old；
- •Patients must have histologically- or cytologically-documented NSCLC who present with locally advanced, unresectable (Stage III) disease;
- •Without prior chemotherapy, radiotherapy, surgery, targeted therapy or immunotherapy;
- •Tumour sample requirements: Mandatory provision of an unstained, archived tumour tissue sample in a quantity sufficient to allow for analysis;
- •A recent tumour biopsy (taken following completion of the most recent therapy) is an optional requirement, provided that a biopsy procedure is technically feasible and the procedure is not associated with unacceptable clinical risk;
- •Life expectancy ≥12 weeks;
- •World Health Organization (WHO) Performance Status of 0 or 1;
- •Evidence of post-menopausal status, or negative urinary or serum pregnancy test for female pre-menopausal patients within 14 days before the use of study drug (HCG has a minimum sensitivity of 25 IU/L or equivalent);
- •Women must be non-breastfeeding
- •Women of reproductive age (WOCBP) must agree to comply with the contraceptive method during the study nivolumab treatment and for a period of 5 months following the last administration of the study treatment (i.e., 30 days [ovulation cycle] plus approximately 5 half-lives of the study drug).
- •Men who have sex with WOCBP must agree to comply with the contraceptive method during the study nivolumab treatment and for 7 months after the last administration of the study treatment (i.e. 90 days [sperm renewal cycle] plus approximately 5 half-life of the study drug).
- •Spermless men do not have to comply with contraceptive requirements. WOCBP who continues to be asexual with the opposite sex does not have to comply with contraceptive requirements, but must still undergo the pregnancy tests described in this section.
- •Adequate organ and marrow function as defined below:
- •Forced expiratory volume in 1 second (FEV1) ≥800ml
- •Absolute neutrophil count >1.5 x 109/L (1500 per mm3)
- •Platelets >100 x 109/L (100,000 per mm3)
- •Haemoglobin≥9.0 g/dL (5.59 mmol/L)
- •Serum creatinine clearance(CL) >50 mL/min by the Cockcroft-Gault formula (Cockcroft and
- •Gault 1976)
- •Serum bilirubin ≤1.5 x upper limit of normal (ULN). ··Aspartate Transaminase(AST) and Alanine Transaminase(ALT) ≤2.5 x ULN
排除标准
- •Exclusion criteria for enrolment for neoadjuvant therapy
- •Patients should not enter the study if any of the following exclusion criteria are fulfilled:
- •Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;
- •Mixed small cell and non-small cell lung cancer histology;
- •Current or prior use of immunosuppressive medication within 28 days before the first dose of Nivolumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
- •Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody;
- •Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of nivolumab;
- •Active or prior documented autoimmune disease within the past 2 years;
- •Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);
- •History of primary immunodeficiency;
- •History of organ transplant that requires therapeutic immunosuppression;
- •Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from3 electrocardiograms (ECGs) using Bazett's Correction;
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;
- •Known history of tuberculosis;
- •Receipt of live attenuated vaccination within 30 days prior to study entry or within30 days of receiving nivolumab;
- •History of another primary malignancy within 5 years prior to starting nivolumab, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;
- •Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control;
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of the nivolumab or interpretation of patient safety or study results.
- •Exclusion criteria for concurrent chemoradiation following neoadjuvant therapy
- •Patients should not enter the concurrent chemoradiation phase if any of the following exclusion criteria are fulfilled:
- •Patients who develop distant metastasis;
- •Patients who develop locoregional disease progression and the irradiation dose of normal tissue will exceed the limit as defined in Section
- •World Health Organization (WHO) Performance Status of 2-4;
- •Inadequate organ and marrow function as defined below:
- •Forced expiratory volume in 1 second (FEV1) <800ml
- •Absolute neutrophil count <1.5 x 109/L (1500 per mm3)
- •Platelets <100 x 109/L (100,000 per mm3)
- •Haemoglobin<9.0 g/dL (5.59 mmol/L)
- •Serum creatinine CL <50 mL/min by the Cockcroft-Gault formula (Cockcroft and
- •Gault 1976)
- •Serum bilirubin >1.5 x upper limit of normal (ULN).
- •Aspartate Transaminase(AST) and Alanine Transaminase(ALT) >2.5 x ULN
- •Further exclusion criteria for randomization into Nivolumab consolidation or observation group
- •Patients should not enter the randomization if any of the following exclusion criteria are fulfilled:
- •Patients who have progressed whilst definitive platinum based, concurrent chemoradiation therapy;
- •Current or prior use of immunosuppressive medication within 28 days before the first dose of Nivolumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid. Systemic steroid administration required to manage toxicities arising from radiation therapy delivered as part of the chemoradiation therapy for locally advanced NSCLC is allowed.
- •Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy will be excluded from randomization;
- •Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded from randomization; Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE>Grade 1.
研究组 & 干预措施
Nivolumab Consolidation
Experimental
Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Neoadjuvant therapy (Other)
Nivolumab Consolidation
Experimental
Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Chemotherapy concurrent with radiotherapy (Other)
Nivolumab Consolidation
Experimental
Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Radiotherapy (Radiation)
Nivolumab Consolidation
Experimental
Patients in experimental group will receive Nivolumab consolidation (360 mg) via iv infusion Q3W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Nivolumab (Drug)
Observation
Active Comparator
Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Neoadjuvant therapy (Other)
Observation
Active Comparator
Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Chemotherapy concurrent with radiotherapy (Other)
Observation
Active Comparator
Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Radiotherapy (Radiation)
Observation
Active Comparator
Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
干预措施: Observation (Other)
结局指标
主要结局
Progression-free Survival
时间窗: 2 years
To assess the efficacy of Nivolumab consolidation compared with observation in terms of progression-free survival
次要结局
- Overall Survival(2 years)
- Overall Survival(OS)(2 years)
- Objective Response Rate(ORR)(2 years)
- Adverse Event(2 years)
- Symptoms and Health-related Quality of Life(2 years)
- Progression-free Survival(2 years)
研究者
Hui Liu
Prof
Sun Yat-sen University
研究点 (3)
Loading locations...
相似试验
终止
2 期
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory MyelomaRelapsed Multiple MyelomaRefractory Multiple MyelomaNCT04119336Andrew Yee, MD2
已完成
2 期
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)Pan TumorNCT03668119Bristol-Myers Squibb212
进行中（未招募）
2 期
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryVulvar MelanomaMucosal MelanomaNCT05111574National Cancer Institute (NCI)101
已完成
2 期
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsMesothelioma, MalignantNCT05136677Bristol-Myers Squibb102
已完成
2 期
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadMicrosatellite Unstable Colorectal CancerMicrosatellite Stable Colorectal CancerMismatch Repair Proficient Colorectal CancerMismatch Repair Deficient Colorectal CancerNCT02060188Bristol-Myers Squibb385